Tests vepugratinib with standard drugs for bladder cancer that has spread
Tests vepugratinib with other cancer drugs in adults with advanced bladder cancer.
Plain-language title generated from the registry record
Registry title: A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract
Key facts
- Where
- Kaohsiung City, Kaohsiung Niao Sung Dist, Taichung, Tainan, Taipei, and Taoyuan, TaiwanSee the 11 sites
- Phase
- Phase 3
Where in Taiwan
- Kaohsiung Medical University Chung-Ho Memorial HospitalKaohsiung City, TaiwanTaking people
- Chang Gung Memorial Hospital at KaohsiungKaohsiung Niao Sung Dist, TaiwanTaking people
- China Medical University HospitalTaichung, TaiwanTaking people
- Taichung Veterans General HospitalTaichung, TaiwanTaking people
- Chi Mei Hospital - Liouying BranchTainan, TaiwanTaking people
- Chi Mei Medical CenterTainan, TaiwanTaking people
- National Cheng Kung University HospitalTainan, TaiwanNot yet recruiting
- National Taiwan University Cancer Center (NTUCC)Taipei, TaiwanTaking people
- National Taiwan University HospitalTaipei, TaiwanTaking people
- Taipei Veterans General HospitalTaipei, TaiwanTaking people
- Chang Gung Medical Foundation-Linkou BranchTaoyuan, TaiwanTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Eli Lilly and Company
- Trial code
- NCT07218380EU 2025-522855-25-00
- Record updated
- 7 October 2026
- Original description
The purpose of this study is to test a new medicine, vepugratinib, in comparison with placebo, to see if it is safe and can help people with a bladder cancer that is advanced or has spread.Read full original descriptionShow less
FORAGER-2: A Phase 3, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Vepugratinib Combined With Enfortumab Vedotin and Pembrolizumab in Adults With Untreated Locally Advanced or Metastatic Urothelial Carcinoma With an FGFR3 Genetic Alteration
The purpose of this study is to test a new medicine, vepugratinib, in comparison with placebo, to see if it is safe and can help people with a bladder cancer that is advanced or has spread.
Vepugratinib or placebo will be administered in combination with enfortumab vedotin and pembrolizumab.
Study participation could last up to approximately 6 years.
Inclusion: Have histologically confirmed, unresectable locally advanced or metastatic urothelial cancer (mUC). Individuals with mixed histology other than small cell or neuroendocrine carcinoma are eligible if a urothelial component is present; Have a qualifying fibroblast growth factor receptor 3 (FGFR3) genetic alteration determined via molecular testing from a tumor or blood sample obtained at or any time after diagnosis of advanced or metastatic urothelial cancer; Have measurable disease by investigator assessment defined by Response Evaluation Criteria in Solid Tumors (RECIST) v1.1; Have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2; Have adequate laboratory parameters.
Exclusion: Have received prior systemic therapy for locally advanced or metastatic urothelial cancer (mUC); Have any unresolved toxicities greater than Grade 1 Common Terminology Criteria for Adverse Events ([CTCAE] version 5.0) from prior neoadjuvant or adjuvant systemic therapy; Have untreated or uncontrolled central nervous system (CNS) involvement or any history of leptomeningeal disease; Current evidence corneal keratopathy or retinal disorder confirmed by ocular examination at screening; Have ongoing sensory or motor neuropathy of Grade 2 or higher.